LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

Ionis Pharmaceuticals Inc

Închisă

SectorSănătate

71.42 2.25

Rezumat

Modificarea prețului

24h

Curent

Minim

70.74

Maxim

71.5

Indicatori cheie

By Trading Economics

Venit

-252M

-129M

Vânzări

-295M

157M

EPS

-0.613

Marjă de profit

-82.062

Angajați

1,069

EBITDA

-263M

-112M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+21.46% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

-370M

11B

Deschiderea anterioară

69.17

Închiderea anterioară

71.42

Sentimentul știrilor

By Acuity

50%

50%

185 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Ionis Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 nov. 2025, 17:45 UTC

Câștiguri
Principalele dinamici ale pieței

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov. 2025, 17:31 UTC

Câștiguri
Principalele dinamici ale pieței

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14 nov. 2025, 16:15 UTC

Principalele dinamici ale pieței

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

14 nov. 2025, 23:56 UTC

Achiziții, Fuziuni, Preluări

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov. 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov. 2025, 22:35 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov. 2025, 22:32 UTC

Achiziții, Fuziuni, Preluări

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov. 2025, 22:29 UTC

Câștiguri

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov. 2025, 22:00 UTC

Achiziții, Fuziuni, Preluări

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov. 2025, 21:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

14 nov. 2025, 21:18 UTC

Achiziții, Fuziuni, Preluări

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov. 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov. 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov. 2025, 20:17 UTC

Achiziții, Fuziuni, Preluări

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov. 2025, 19:29 UTC

Market Talk
Câștiguri

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov. 2025, 18:44 UTC

Market Talk
Câștiguri

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov. 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14 nov. 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov. 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov. 2025, 17:20 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

14 nov. 2025, 17:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Health Care Roundup: Market Talk

14 nov. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14 nov. 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov. 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 nov. 2025, 16:38 UTC

Market Talk

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14 nov. 2025, 16:30 UTC

Achiziții, Fuziuni, Preluări

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14 nov. 2025, 16:28 UTC

Market Talk

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

14 nov. 2025, 15:59 UTC

Market Talk

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

14 nov. 2025, 15:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 nov. 2025, 15:06 UTC

Market Talk

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Comparație

Modificare preț

Ionis Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

21.46% sus

Prognoză pe 12 luni

Medie 84.83 USD  21.46%

Maxim 110 USD

Minim 65 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIonis Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

20 ratings

17

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

29.78 / 33.645Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Very Strong Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

185 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat